4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol has been researched along with Acute Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braun, V; Meyer, FP; Neuhof, S; Ulrich, S | 1 |
| Gaertner, HJ; Mahal, A; Stevens, A; Stevens, I | 1 |
2 trial(s) available for 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and Acute Disease
| Article | Year |
|---|---|
Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Interactions; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia | 1999 |
Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis.
Topics: Acute Disease; Adult; Drug Therapy, Combination; Female; Haloperidol; Humans; Lorazepam; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1992 |